These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33341450)

  • 1. Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.
    den Uil SH; de Wit M; Slebos RJC; Delis-van Diemen PM; Sanders J; Piersma SR; Pham TV; Coupé VMH; Bril H; Stockmann HBAC; Jimenez CR; Meijer GA; Fijneman RJA
    Eur J Cancer; 2021 Feb; 144():91-100. PubMed ID: 33341450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
    Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
    N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer.
    Cecchini MJ; Walsh JC; Parfitt J; Chakrabarti S; Correa RJ; MacKenzie MJ; Driman DK
    Hum Pathol; 2019 Aug; 90():70-79. PubMed ID: 31121192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.
    Derangère V; Lecuelle J; Lepage C; Aoulad-Ben Salem O; Allatessem BM; Ilie A; Bouché O; Phelip JM; Baconnier M; Pezet D; Sebbagh V; Terrebonne E; Bouard G; Jooste V; Bouvier AM; Molimard C; Monnien F; Gonzalez D; Le Malicot K; Rageot D; Truntzer C; Bibeau F; Ghiringhelli F;
    Eur J Cancer; 2022 Sep; 172():221-230. PubMed ID: 35785606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts.
    Hansen TF; Kjær-Frifeldt S; Eriksen AC; Lindebjerg J; Jensen LH; Sørensen FB; Jakobsen A
    Br J Cancer; 2018 Nov; 119(11):1367-1373. PubMed ID: 30425348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
    Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
    Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.
    Aydin SG; Olmez OF; Selvi O; Geredeli C; Ozden F; Bilici A; Acikgoz O; Karci E; Kutlu Y; Hamdard J; Aydin A
    J Gastrointest Cancer; 2024 Mar; 55(1):227-236. PubMed ID: 37347353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.
    Hestetun KE; Aasebø K; Rosenlund NB; Müller Y; Dahl O; Myklebust MP
    Mod Pathol; 2021 Jan; 34(1):161-170. PubMed ID: 32737450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer.
    Bennedsen ALB; Cai L; Hasselager RP; Özcan AA; Mohamed KB; Eriksen JO; Eiholm S; Bzorek M; Fiehn AK; Hviid TVF; Gögenur I
    BMC Cancer; 2022 Jan; 22(1):62. PubMed ID: 35027037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDX2 Protein Expression in Colorectal Cancer and ItsCorrelation with Clinical and Pathological Characteristics, Prognosis, and Survival Rate of Patients.
    Asgari-Karchekani S; Karimian M; Mazoochi T; Taheri MA; Khamehchian T
    J Gastrointest Cancer; 2020 Sep; 51(3):844-849. PubMed ID: 31630373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of CDX2 and Villin Expression in Advanced Stage Colorectal Carcinoma.
    Altintas S; Bayrak M; Altintas Y
    J Coll Physicians Surg Pak; 2019 Nov; 29(11):1057-1061. PubMed ID: 31659962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer.
    Xu W; Zhu Y; Shen W; Ding W; Wu T; Guo Y; Chen X; Zhou M; Chen Y; Cui L; Du P
    J Int Med Res; 2019 May; 47(5):1829-1842. PubMed ID: 30616445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
    Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
    Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker.
    Zougman A; Hutchins GG; Cairns DA; Verghese E; Perry SL; Jayne DG; Selby PJ; Banks RE
    Eur J Cancer; 2013 Jan; 49(2):531-9. PubMed ID: 23021913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
    Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
    Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
    BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDX2 downregulation is associated with poor differentiation and MMR deficiency in colon cancer.
    Olsen J; Eiholm S; Kirkeby LT; Espersen ML; Jess P; Gögenür I; Olsen J; Troelsen JT
    Exp Mol Pathol; 2016 Feb; 100(1):59-66. PubMed ID: 26551082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
    Pilati C; Taieb J; Balogoun R; Marisa L; de Reyniès A; Laurent-Puig P
    Ann Oncol; 2017 May; 28(5):1032-1035. PubMed ID: 28328000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic relevance of Src activation in stage II-III colon cancer.
    Martínez-Pérez J; Lopez-Calderero I; Saez C; Benavent M; Limon ML; Gonzalez-Exposito R; Soldevilla B; Riesco-Martínez MC; Salamanca J; Carnero A; Garcia-Carbonero R
    Hum Pathol; 2017 Sep; 67():119-125. PubMed ID: 28601656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.